Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation
German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for...
InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...
Uni-Bio Science’s Generic Diquas Accepted for NMPA Review
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
MicusRx’s Contezolid Sodium NDA Accepted for Review by NMPA
China-based Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) announced that a New Drug Application (NDA)...
Sanofi to Acquire Vigil Neuroscience to Boost Neurology Pipeline
French pharmaceutical giant Sanofi (NASDAQ: SNY) is set to acquire US-based Vigil Neuroscience, Inc., a...
Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment
The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...
Shanghai INT Medical Instruments to Acquire Majority Stake in Endonom Medical
China-based Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) is set to jointly acquire a...
Medtronic Reports Q4 and FY2025 Results with Revenue Growth Across Key Segments
US-Irish firm Medtronic (NYSE: MDT) released financial results for its fourth quarter (Q4) and fiscal...
Genentech and Orionis Enter Second Collaboration on Small-Molecule Oncology Drugs
Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY), this week entered...
Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...
Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment
Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...
Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...
Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance
Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...
Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia
Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...
Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...
Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...
HHS Implements Trump’s Order for Most-Favored-Nation Drug Pricing
The U.S. Department of Health and Human Services (HHS) announced that it is taking immediate...
Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study
China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...
AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...